| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-12 16:15:46 UTC |
|---|
| Updated at | 2022-09-12 16:15:46 UTC |
|---|
| NP-MRD ID | NP0330681 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | (1s,2r,3s,5s,6s,16e,18e,20r,21s)-11-chloro-21,23-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1¹⁰,¹⁴.0³,⁵]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 2-methylpropanoate |
|---|
| Description | Ansamitocin P3, also known as C15003P3, belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides. Thus, ansamitocin P3 is considered to be a macrolide. Ansamitocin P3 is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. (1s,2r,3s,5s,6s,16e,18e,20r,21s)-11-chloro-21,23-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1¹⁰,¹⁴.0³,⁵]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 2-methylpropanoate is found in Actinosynnema pretiosum. (1s,2r,3s,5s,6s,16e,18e,20r,21s)-11-chloro-21,23-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1¹⁰,¹⁴.0³,⁵]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 2-methylpropanoate was first documented in 1992 (PMID: 1517150). Based on a literature review a significant number of articles have been published on ansamitocin P3 (PMID: 11071278) (PMID: 1530630) (PMID: 15533675) (PMID: 15674857) (PMID: 20235129) (PMID: 20980145). |
|---|
| Structure | CO[C@@H]1\C=C\C=C(C)\CC2=CC(N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]3(C)O[C@H]3[C@H](C)[C@@H]3C[C@@]1(O)N=C(O)O3)=C(Cl)C(OC)=C2 InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)/b11-9+,18-10+/t19-,23+,24-,25+,28+,31+,32+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 2'-De(acetylmethylamino)-2'-methylmaytansine | ChEBI | | Ansamitocin p-3 | ChEBI | | Antibiotic C15003P3 | ChEBI | | C15003P3 | ChEBI | | Maytansinol isobutyrate | ChEBI | | Ansamitosin p-3 | Kegg | | Maytansinol isobutyric acid | Generator | | Ansamitocins | MeSH | | Ansamitocin p 3 | MeSH | | Ansamitocin p 4 | MeSH | | Ansamitomicin p-3 | MeSH | | Ansamitocin p 3' | MeSH |
|
|---|
| Chemical Formula | C32H43ClN2O9 |
|---|
| Average Mass | 635.1500 Da |
|---|
| Monoisotopic Mass | 634.26571 Da |
|---|
| IUPAC Name | (1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21,23-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1^{10,14}.0^{3,5}]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 2-methylpropanoate |
|---|
| Traditional Name | (1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21,23-dihydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8-oxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1^{10,14}.0^{3,5}]hexacosa-10,12,14(26),16,18,22-hexaen-6-yl 2-methylpropanoate |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CO[C@@H]1\C=C\C=C(C)\CC2=CC(N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]3(C)O[C@H]3[C@H](C)[C@@H]3C[C@@]1(O)N=C(O)O3)=C(Cl)C(OC)=C2 |
|---|
| InChI Identifier | InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)/b11-9+,18-10+/t19-,23+,24-,25+,28+,31+,32+/m1/s1 |
|---|
| InChI Key | OPQNCARIZFLNLF-JBHFWYGFSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as macrolactams. These are cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. They are nitrogen analogues (the a nitrogen atom replacing the o atom of the cyclic carboxylic acid group ) of the naturally occurring macrolides. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Macrolactams |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Macrolactams |
|---|
| Alternative Parents | |
|---|
| Substituents | - Macrolactam
- Anisole
- Alkyl aryl ether
- 1,3-oxazinane
- Aryl chloride
- Aryl halide
- Oxazinane
- Benzenoid
- Tertiary carboxylic acid amide
- Carbamic acid ester
- Carboxamide group
- Carboxylic acid ester
- Lactam
- Carbonic acid derivative
- Organoheterocyclic compound
- Azacycle
- Carboxylic acid derivative
- Alkanolamine
- Dialkyl ether
- Oxirane
- Ether
- Oxacycle
- Monocarboxylic acid or derivatives
- Organonitrogen compound
- Organooxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organic oxygen compound
- Carbonyl group
- Organic nitrogen compound
- Organopnictogen compound
- Organohalogen compound
- Organochloride
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Havens CG, Bryant N, Asher L, Lamoreaux L, Perfetto S, Brendle JJ, Werbovetz KA: Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol Biochem Parasitol. 2000 Oct;110(2):223-36. doi: 10.1016/s0166-6851(00)00272-3. [PubMed:11071278 ]
- Okamoto K, Harada K, Ikeyama S, Iwasa S: Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. Jpn J Cancer Res. 1992 Jul;83(7):761-8. doi: 10.1111/j.1349-7006.1992.tb01977.x. [PubMed:1517150 ]
- Li Y, Kobayashi H, Hashimoto Y, Iwasaki S: Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. Biochem Biophys Res Commun. 1992 Sep 16;187(2):722-9. doi: 10.1016/0006-291x(92)91255-o. [PubMed:1530630 ]
- Liu Z, Floss HG, Cassady JM, Xiao J, Chan KK: An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. J Pharm Biomed Anal. 2004 Nov 19;36(4):815-21. doi: 10.1016/j.jpba.2004.07.045. [PubMed:15533675 ]
- Liu Z, Floss HG, Cassady JM, Chan KK: Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 2005 Mar;40(3):389-99. doi: 10.1002/jms.800. [PubMed:15674857 ]
- Yao Y, Cheng Z, Ye H, Xie Y, He J, Tang M, Shen T, Wang J, Zhou Y, Lu Z, Luo F, Chen L, Yu L, Yang JL, Peng A, Wei Y: Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. J Sep Sci. 2010 May;33(9):1331-7. doi: 10.1002/jssc.200900746. [PubMed:20235129 ]
- Lin J, Bai L, Deng Z, Zhong JJ: Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum. Bioresour Technol. 2011 Jan;102(2):1863-8. doi: 10.1016/j.biortech.2010.09.102. Epub 2010 Oct 25. [PubMed:20980145 ]
- Edwards A, Gladstone M, Yoon P, Raben D, Frederick B, Su TT: Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul;4(4):496-503. doi: 10.1242/dmm.006486. Epub 2011 Apr 18. [PubMed:21504911 ]
- Jia Y, Zhong JJ: Enhanced production of ansamitocin P-3 by addition of Mg2+ in fermentation of Actinosynnema pretiosum. Bioresour Technol. 2011 Nov;102(21):10147-50. doi: 10.1016/j.biortech.2011.08.031. Epub 2011 Aug 22. [PubMed:21907573 ]
- LOTUS database [Link]
|
|---|